The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds.The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition.The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid and preferably may be a saturated or unsaturated C10-C18 fatty...

The present invention provides extended release pharmaceutical compositions of a beta blocker such as but not limited to metoprolol succinate as the active ingredient and methods of preparing such extended release pharmaceutical compositions.

Disclosed is an extended release coated granule consisting of a granule having a particle size ranging from 0.2 to 2 mm, a friability lower than or equal to 1 percent and comprising metoprolol succinate as active ingredient in an amount ranging from 10 to 75 percent by weight of the granule before being coated and at least one binder selected from microcrystalline cellulose and methylcellulose, said granule being coated with a film-former coating agent. Also disclosed is a process for preparing ...

This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.

This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.

An extended release pharmaceutical composition comprising metoprolol succinate and at least two pharmaceutically acceptable excipients wherein one pharmaceutically acceptable excipient is an extended release agent; the second pharmaceutically acceptable excipient is selected from a binder a diluent and mixtures thereof; and metoprolol succinate is in a crystalline form having a D50 ranging from 5 to 16 microns and a D90 below 50 microns.